Henriksen Michael, Johnsen Kasper Bendix, Andersen Hjalte Holm, Pilgaard Linda, Duroux Meg
Laboratory for Cancer Biology, Institute of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 3B, 9220, Aalborg Ø, Denmark.
Mol Neurobiol. 2014 Dec;50(3):896-913. doi: 10.1007/s12035-014-8668-y. Epub 2014 Mar 12.
Despite advances in our knowledge about glioblastoma multiforme (GBM) pathology, clinical challenges still lie ahead with respect to treatment in GBM due to high prevalence, poor prognosis, and frequent tumor relapse. The implication of microRNAs (miRNAs) in GBM is a rapidly expanding field of research with the aim to develop more targeted molecular therapies. This review aims to present a comprehensive overview of all the available literature, evaluating miRNA signatures as a function of prognosis and survival in GBM. The results are presented with a focus on studies derived from clinical data in databases and independent tissue cohorts where smaller samples sizes were investigated. Here, miRNA associated to longer survival (protective) and miRNA with shorter survival (risk-associated) have been identified and their signatures based on different prognostic attributes are described. Finally, miRNAs associated with disease progression or survival in several studies are identified and functionally described. These miRNAs may be valuable for future determination of patient prognosis and could possibly serve as targets for miRNA-based therapies, which hold a great potential in the treatment of this severe malignant disease.
尽管我们对多形性胶质母细胞瘤(GBM)病理学的认识有所进展,但由于其高发病率、预后不良和频繁的肿瘤复发,GBM的治疗仍面临临床挑战。微小RNA(miRNA)在GBM中的作用是一个迅速扩展的研究领域,旨在开发更具针对性的分子疗法。本综述旨在全面概述所有现有文献,评估miRNA特征作为GBM预后和生存的函数。结果重点介绍了来自数据库临床数据和研究样本量较小的独立组织队列的研究。在此,已鉴定出与较长生存期相关的miRNA(保护性)和与较短生存期相关的miRNA(风险相关),并描述了基于不同预后属性的特征。最后,在多项研究中鉴定并从功能上描述了与疾病进展或生存相关的miRNA。这些miRNA可能对未来患者预后的确定有价值,并可能作为基于miRNA疗法的靶点,这在治疗这种严重恶性疾病方面具有巨大潜力。